Price movement over the last 24 hours
Albertsons Companies Inc vs Mesoblast Limited — how do they compare? Albertsons Companies Inc trades at $13.98 (market cap $6.93B), while Mesoblast Limited trades at $14.81 (market cap $1.82B). The key difference: Albertsons Companies Inc is far larger — about 3.8× Mesoblast Limited's market cap, and Albertsons Companies Inc pays a 4.81% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| ACI | MESO | |
|---|---|---|
Market Cap | $6.93B | $1.82B |
Sector | Consumer Staples | Technology |
52-Week High | $22.33 | $20.96 |
52-Week Low | $13.45 | $10.45 |
Enterprise Value | $22.02B | $1.82B |
Dividend Yield | 4.81% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $14.33, down 0.35% with a bearish technical signal. The company reported Q1 2025 revenue of $17.20M with a gross margin of 80.52% but significant losses (-$102.14M net income). Recent developments include FDA BLA filing for rexlemestrocel-L in heart failure and a $50M debt facility draw. Analyst consensus shows 45% buy ratings amid high valuation multiples (P/S 30.52).
Outlook hinges on regulatory approvals and commercial execution. The stock offers speculative upside from pipeline catalysts but carries substantial risk from cash burn and clinical trial outcomes. Investors face volatility from binary regulatory events while current fundamentals reflect pre-revenue biotech challenges.
Trailing returns across standard periods
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →